Biomarkers for prostate cancer: prostate-specific antigen and beyond
MJ Duffy - Clinical Chemistry and Laboratory Medicine (CCLM), 2020 - degruyter.com
In recent years, several new biomarkers supplementing the role of prostate-specific antigen
(PSA) have become available for men with prostate cancer. Although widely used in an ad …
(PSA) have become available for men with prostate cancer. Although widely used in an ad …
EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent
N Mottet, J Bellmunt, M Bolla, E Briers… - European urology, 2017 - Elsevier
Objective To present a summary of the 2016 version of the European Association of Urology
(EAU)-European Society for Radiotherapy & Oncology (ESTRO)-International Society of …
(EAU)-European Society for Radiotherapy & Oncology (ESTRO)-International Society of …
All change in the prostate cancer diagnostic pathway
DJ Lomas, HU Ahmed - Nature reviews Clinical oncology, 2020 - nature.com
Following detection of high levels of serum prostate-specific antigen, many men are advised
to have transrectal ultrasound-guided biopsy in an attempt to locate a cancer. This …
to have transrectal ultrasound-guided biopsy in an attempt to locate a cancer. This …
Assessing the clinical impact of risk prediction models with decision curves: guidance for correct interpretation and appropriate use
The decision curve is a graphical summary recently proposed for assessing the potential
clinical impact of risk prediction biomarkers or risk models for recommending treatment or …
clinical impact of risk prediction biomarkers or risk models for recommending treatment or …
Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study
Background The prostate-specific antigen (PSA) test is used to screen for prostate cancer
but has a high false-positive rate that translates into unnecessary prostate biopsies and …
but has a high false-positive rate that translates into unnecessary prostate biopsies and …
NCCN guidelines insights: prostate cancer early detection, version 2.2016
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer
Early Detection provide recommendations for prostate cancer screening in healthy men who …
Early Detection provide recommendations for prostate cancer screening in healthy men who …
Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer
Background Screening for prostate cancer using prostate-specific antigen (PSA) alone leads
to un-necessary biopsying and overdiagnosis. PSA density is easily accessible, but early …
to un-necessary biopsying and overdiagnosis. PSA density is easily accessible, but early …
Prostate cancer screening
WJ Catalona - Medical Clinics, 2018 - medical.theclinics.com
The US Preventive Services Task Force (USPSTF) has dropped its opposition to routine
prostate cancer (PCa) screening in favor of a shared decision-making process between men …
prostate cancer (PCa) screening in favor of a shared decision-making process between men …
Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised …
Background Screening for prostate cancer using prostate-specific antigen (PSA) reduces
prostate cancer mortality but can lead to adverse outcomes. We aimed to compare a …
prostate cancer mortality but can lead to adverse outcomes. We aimed to compare a …
[HTML][HTML] Diagnostic accuracy of liquid biomarkers for clinically significant prostate cancer detection: a systematic review and diagnostic meta-analysis of multiple …
Context Many liquid biomarkers have entered clinical practice with the praise to improve the
detection of clinically significant prostate cancer (csPCa), hel** avoid unnecessary …
detection of clinically significant prostate cancer (csPCa), hel** avoid unnecessary …